Replies to post #212824 on Biotech Values

[DewDiligence]

TEVA—(-18%)—slashes 2017 guidance and cuts dividend 75%:

https://finance.yahoo.com/news/teva-reports-second-quarter-2017-103000375.html

We have lowered our outlook for 2017 Non-GAAP results to revenues of $22.8 – $23.2 billion from a previously expected range of $23.8 – $24.5 billion [i.e. a $1B cut at the low end of the range and a $1.3B cut at the high end of the range].

Non-GAAP EPS for 2017 is now expected to be $4.30 – $4.50…down from a previously expected range of $4.90 – $5.30 [a 14% cut at the midpoints of the old and new ranges.

[DewDiligence]

TEVA’s new CEO is Lundbeck’s Kare Schultz:

https://www.reuters.com/article/us-teva-pharm-ind-ceo/israels-teva-pharma-appoints-lundbecks-kare-schultz-as-ceo-idUSKCN1BM0LU